Janux Therapeutics Inc (JANX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Janux Therapeutics Inc (JANX) has a cash flow conversion efficiency ratio of -0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.34 Million) by net assets ($941.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Janux Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Janux Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Janux Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Janux Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Janux Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
0.097x |
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
0.242x |
|
Cansino Biologics Inc
SHG:688185
|
0.003x |
|
BURFORD CAPITAL LTD
F:9BFA
|
-0.090x |
|
Sichuan Shudao Equipment & Technology Co Ltd
SHE:300540
|
-0.073x |
|
Air New Zealand Ltd
AU:AIZ
|
0.117x |
|
Shenzhen Infinova Ltd
SHE:002528
|
-0.364x |
|
JBG SMITH Properties
NYSE:JBGS
|
0.002x |
Annual Cash Flow Conversion Efficiency for Janux Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Janux Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Janux Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $956.82 Million | $-82.23 Million | -0.086x | -100.63% |
| 2024-12-31 | $1.02 Billion | $-43.81 Million | -0.043x | +70.83% |
| 2023-12-31 | $344.35 Million | $-50.58 Million | -0.147x | -9.75% |
| 2022-12-31 | $320.74 Million | $-42.92 Million | -0.134x | -188.78% |
| 2021-12-31 | $366.33 Million | $-16.98 Million | -0.046x | -115.53% |
| 2020-12-31 | $-14.64 Million | $-4.37 Million | 0.298x | -38.06% |
| 2019-12-31 | $-7.94 Million | $-3.83 Million | 0.482x | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more